Standard of Care: Managing and Treating CHI
Last updated:
The standard of care for Congenital Hyperinsulinism (CHI) involves immediate blood sugar stabilization with dextrose or glucagon, followed by medical therapy like diazoxide. If medications fail, genetic testing and scans guide targeted or near-total surgical removal of the pancreas.
Key Takeaways
- • Immediate stabilization with high-concentration dextrose or glucagon is the critical first step in managing CHI.
- • Feeding tubes are a common and effective tool to ensure children receive consistent carbohydrates without the stress of constant oral feeding.
- • Diazoxide is the primary medical therapy, but it requires careful monitoring for side effects like pulmonary hypertension.
- • Focal CHI can often be cured with targeted surgery that preserves most of the pancreas.
- • Diffuse CHI may require a near-total pancreatectomy if medications fail, which manages the condition but typically causes insulin-dependent diabetes.
Managing Congenital Hyperinsulinism (CHI) requires a step-by-step approach that moves from immediate stabilization to long-term control. The goal is always the same: maintain safe blood sugar levels to protect the brain while minimizing side effects [1][2].
Step 1: Immediate Stabilization
When a baby is first diagnosed, the priority is to stop the dangerous “lows.”
- High-Concentration Dextrose: Babies often need a very high amount of intravenous (IV) sugar to keep up with the excess insulin [3][4].
- Glucagon: This hormone works as an “anti-insulin,” telling the liver to release stored sugar. It can be given as a continuous IV infusion in the hospital. Additionally, glucagon can also be prescribed as an emergency at-home intramuscular or subcutaneous rescue injection for sudden severe lows [1][4].
The Role of Feeding and Nutrition
Because CHI involves constant insulin, frequent and consistent carbohydrates are often required to prevent lows. Many children require continuous overnight feeding or strict daytime feeding schedules. To ease the burden of round-the-clock feeds, the care team may recommend a Nasogastric (NG) tube (a tube through the nose to the stomach) or a Gastrostomy (G) tube (a tube placed directly into the stomach). While the idea of a feeding tube can be daunting, many parents find it becomes a vital tool that helps ensure their child gets the necessary sugar without the constant stress of forced oral feeding [5][3].
Step 2: First-Line Medical Therapy (Diazoxide)
Diazoxide is the first medication most children try. It works by acting on the KATP channels (the “gates”) in the pancreas, helping them stay open to stop insulin release [6][7].
- Common Side Effects: Most children will experience hypertrichosis (excessive hair growth on the forehead, back, or limbs) and some fluid retention (swelling) [8][9].
- Serious Risk: A rare but severe side effect is pulmonary hypertension (high blood pressure in the lungs), which affects about 2% of children on the drug. Doctors should monitor your child’s heart and breathing closely when starting this medication [10][8].
Step 3: Second-Line Medical Therapy (Octreotide & Sirolimus)
If diazoxide does not work (often called “diazoxide-resistant” CHI), other medications are used:
- Octreotide: This is an injection that signals the pancreas to suppress insulin [11]. Side effects can include gallbladder stones and, in rare cases, a serious intestinal issue called necrotizing enterocolitis (NEC) in newborns [12][13].
- Sirolimus: For children who do not respond to other drugs, this “mTOR inhibitor” is sometimes used to avoid surgery. It requires careful monitoring because it can suppress the immune system [3][14].
Step 4: Surgical Options
The type of surgery depends entirely on whether the CHI is Focal or Diffuse [15].
- Focal CHI (Targeted Lesionectomy): A surgeon removes just the localized cluster of cells. This is curative in up to 97% of cases, and because the rest of the pancreas is left intact, these children typically do not develop diabetes or digestive issues [15][16].
- Diffuse CHI (Subtotal Pancreatectomy): If the entire pancreas is affected and medications aren’t working, removing 95-98% of the pancreas may be necessary. This is not a cure, but a way to make the hypoglycemia manageable. Most children who undergo this surgery will eventually develop insulin-dependent diabetes and exocrine insufficiency (the inability to digest food properly without taking replacement enzymes) [17][18].
The Treatment Decision Tree
A high-quality care team will follow a standard chronological order to protect your child:
- Start Diazoxide: Initiated almost immediately upon diagnosis to attempt medical control while waiting weeks for rapid genetic results [15].
- Evaluate Genetics & Meds: If Diazoxide fails OR genetics point to a paternal focal mutation \u2192 Proceed to 18F-DOPA PET/CT Scan [15].
- If Focal: Proceed to Targeted Lesionectomy (Cure) [15].
- If Diffuse: Try second-line medications (Octreotide, Sirolimus). If all fail \u2192 Consider Subtotal Pancreatectomy to prevent brain injury [3].
Warning: Attempting a “blind” surgery (removing parts of the pancreas without a PET scan or genetic guidance) is outdated and significantly increases the risk of complications. Always ensure your child is at a specialized center [15][19].
Frequently Asked Questions
What is the first-line medication for congenital hyperinsulinism?
Why might my baby need a feeding tube for CHI?
What are the side effects of taking diazoxide?
What is the difference between focal and diffuse CHI surgery?
What happens if my child is diazoxide-resistant?
Questions for Your Doctor
- • Is my child's CHI 'diazoxide-responsive' or 'diazoxide-resistant,' and what does that mean for our long-term plan?
- • Before we start diazoxide, will my child have an echocardiogram to check for pulmonary hypertension?
- • If my child has a focal lesion, is this surgeon experienced specifically in 'tissue-sparing lesionectomy'?
- • What is the specific risk of my child developing diabetes if we proceed with a subtotal pancreatectomy?
- • If we use octreotide, how will we monitor for side effects like gallbladder stones or necrotizing enterocolitis (NEC)?
- • At what point should we consider placing an NG-tube or G-tube to help manage the feeding schedule?
Questions for You
- • Do I have a written plan for what to do if my child's blood sugar does not rise after a 'rescue' dose of glucose or glucagon at home?
- • How am I tracking my child's side effects (like hair growth or swelling) so I can report them accurately to the endocrinologist?
- • Have I discussed the possibility of a 'G-tube' (feeding tube) with the care team to ease the burden of strict round-the-clock feedings?
Want personalized information?
Type your question below to get evidence-based answers tailored to your situation.
References
- 1
Congenital Hyperinsulinism.
Sims K
NeoReviews 2021; (22(4)):e230-e240 doi:10.1542/neo.22-4-e230.
PMID: 33795398 - 2
Congenital hyperinsulinism in clinical practice: From biochemical pathophysiology to new monitoring techniques.
Martino M, Sartorelli J, Gragnaniello V, Burlina A
Frontiers in pediatrics 2022; (10()):901338 doi:10.3389/fped.2022.901338.
PMID: 36210928 - 3
Sirolimus in infants with congenital hyperinsulinism (CHI) - a single-centre experience.
Panigrahy N, Chirla DK, Bagga N, et al.
European journal of pediatrics 2022; (181(1)):407-412 doi:10.1007/s00431-021-04209-6.
PMID: 34304300 - 4
Congenital hyperinsulinism associated with Hirschsprung's disease-a report of an extremely rare case.
Shono T, Shono K, Hashimoto Y, et al.
Surgical case reports 2020; (6(1)):4 doi:10.1186/s40792-020-0778-3.
PMID: 31916119 - 5
Congenital Hyperinsulinism International: A Community Focused on Improving the Lives of People Living With Congenital Hyperinsulinism.
Raskin J, Pasquini TLS, Bose S, et al.
Frontiers in endocrinology 2022; (13()):886552 doi:10.3389/fendo.2022.886552.
PMID: 35573986 - 6
A new familial form of a late-onset, persistent hyperinsulinemic hypoglycemia of infancy caused by a novel mutation in KCNJ11.
Yang YY, Long RK, Ferrara CT, et al.
Channels (Austin, Tex.) 2017; (11(6)):636-647 doi:10.1080/19336950.2017.1393131.
PMID: 29087246 - 7
Pharmacological Correction of Trafficking Defects in ATP-sensitive Potassium Channels Caused by Sulfonylurea Receptor 1 Mutations.
Martin GM, Rex EA, Devaraneni P, et al.
The Journal of biological chemistry 2016; (291(42)):21971-21983 doi:10.1074/jbc.M116.749366.
PMID: 27573238 - 8
Efficacy and safety of diazoxide for treating hyperinsulinemic hypoglycemia: A systematic review and meta-analysis.
Chen X, Feng L, Yao H, et al.
PloS one 2021; (16(2)):e0246463 doi:10.1371/journal.pone.0246463.
PMID: 33571197 - 9
Necrotizing Enterocolitis in Neonates With Hyperinsulinemic Hypoglycemia Treated With Diazoxide.
Keyes ML, Healy H, Sparger KA, et al.
Pediatrics 2021; (147(2)) doi:10.1542/peds.2019-3202.
PMID: 33483452 - 10
Prevalence of Adverse Events in Children With Congenital Hyperinsulinism Treated With Diazoxide.
Herrera A, Vajravelu ME, Givler S, et al.
The Journal of clinical endocrinology and metabolism 2018; (103(12)):4365-4372 doi:10.1210/jc.2018-01613.
PMID: 30247666 - 11
Congenital Hyperinsulinaemic Hypoglycaemia-A Review and Case Presentation.
Krawczyk S, Urbanska K, Biel N, et al.
Journal of clinical medicine 2022; (11(20)) doi:10.3390/jcm11206020.
PMID: 36294341 - 12
Octreotide efficacy and safety in children with hyperinsulinism: evidence from two Chinese centers.
Ni J, Cao B, Zeng H, et al.
European journal of pediatrics 2024; (184(1)):33 doi:10.1007/s00431-024-05884-x.
PMID: 39565408 - 13
Late Presentation of Fulminant Necrotizing Enterocolitis in a Child with Hyperinsulinism on Octreotide Therapy.
Hawkes CP, Adzick NS, Palladino AA, De León DD
Hormone research in paediatrics 2016; (86(2)):131-136 doi:10.1159/000443959.
PMID: 26867223 - 14
Sirolimus: Efficacy and Complications in Children With Hyperinsulinemic Hypoglycemia: A 5-Year Follow-Up Study.
Maria G, Antonia D, Michael A, et al.
Journal of the Endocrine Society 2019; (3(4)):699-713 doi:10.1210/js.2018-00417.
PMID: 30882046 - 15
Congenital hyperinsulinism: localization of a focal lesion with 18F-FDOPA positron emission tomography.
States LJ, Becker SA, De León DD
Pediatric radiology 2022; (52(4)):693-701 doi:10.1007/s00247-021-05206-5.
PMID: 34668049 - 16
Subtotal Pancreatectomy for Congenital Hyperinsulinism: Our Experience and Review of Literature.
Redkar R, Karkera PJ, Krishnan J, Hathiramani V
The Indian journal of surgery 2015; (77(Suppl 3)):778-82 doi:10.1007/s12262-013-0999-9.
PMID: 27011456 - 17
Therapies and outcomes of congenital hyperinsulinism-induced hypoglycaemia.
Banerjee I, Salomon-Estebanez M, Shah P, et al.
Diabetic medicine : a journal of the British Diabetic Association 2019; (36(1)):9-21 doi:10.1111/dme.13823.
PMID: 30246418 - 18
Reassessing Pancreatectomy in Diffuse Congenital Hyperinsulinism: A Tale of 2 Brothers With Homozygous KCNJ11 Variants.
Rafique HA, Lucas-Herald AK, Shaikh MG
JCEM case reports 2025; (3(4)):luaf045 doi:10.1210/jcemcr/luaf045.
PMID: 40110568 - 19
F-18 DOPA PET/CT in pediatric patients with hyperinsulinemic hypoglycemia: A correlation with genetic analysis.
Sagar S, Arora G, Damle N, et al.
Nuclear medicine communications 2022; (43(4)):451-457 doi:10.1097/MNM.0000000000001526.
PMID: 35045547
This page provides educational information about the standard of care for congenital hyperinsulinism. Always consult your pediatric endocrinologist and specialized care team for medical advice tailored to your child's specific diagnosis.
Stay up to date
Get notified when new research about Congenital isolated hyperinsulinism is published.
No spam. Unsubscribe anytime.